Epidemiology and management of hypertension in the hispanic population: a review of the available literature
American Journal of Cardiovascular Drugs, 05/31/2012
Guzman NJ – Additional studies are needed to more thoroughly evaluate the effects of renin–angiotensin–aldosterone system (RAAS) inhibitors (and other drug classes) on outcomes and blood pressure (BP) lowering in the Hispanic hypertensive population.
- Hispanics are the fastest growing ethnic minority in the USA.
- Among Hispanics, lack of hypertension awareness and lack of effective blood pressure (BP) control are problematic, as are higher incidence rates of hypertension–related co–morbidities compared with non–Hispanic populations.
- Moreover, there are currently no hypertension treatment guidelines that address the unique characteristics of this ethnic group.
- This article discusses ethnic differences in hypertension and cardiovascular risk factors and reviews the literature on the efficacy of antihypertensive agents in Hispanic patients, with a focus on the role of renin–angiotensin–aldosterone system (RAAS) inhibition in the management of hypertension in these patients.
- Hypertension in Hispanic patients can be challenging to manage, in part because this population has a higher prevalence of obesity, diabetes, and metabolic syndrome compared with non–Hispanic whites.
- The presence of these co–morbidities suggests that RAAS–inhibitor–based therapies may be particularly beneficial in this population.
- However, few studies have evaluated the efficacy of antihypertensive treatments in Hispanic patients.
- Two outcomes studies in hypertensive patients have shown the benefits of treating Hispanic patients with antihypertensive therapy and included RAAS inhibitors as part of the treatment regimen.
- In addition, BP–lowering trials have shown the antihypertensive efficacy of angiotensin–converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors, although data on the latter are more limited.